我要投票 正韩在鹿茸行业中的票数:711
· 外 推 电 报 ·
2026-01-16 09:11:41 星期五

【正韩是哪个国家的品牌?】

正韩是什么牌子?「正韩」是 广东正韩药业股份有限公司 旗下著名品牌。该品牌发源于广东省茂名市,由创始人刘 *在2001年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力正韩品牌出海!将品牌入驻外推网,定制正韩品牌推广信息,可以显著提高正韩产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

正韩集团旗下广东正韩药业股份有限公司,以长白朝鲜族自治县为生产原料种植、采集基地,茂名为深加工,大韩正韩(香港)国际集团公司为营销窗口综合发展的企业集团。企业引进精良的生产设备,设立流水生产线车间,通过独特的古法炮制工艺与现代制药生产技术有效结合进行生产。

历经近20多年的稳健发展,生产经营“正韩牌、一宫庄牌、正山庄牌”等品牌参茸贵细产品已形成品牌,占据行业龙头地位并远销世界各国。

公司自成立以来,以“奉献健康,创造和谐”为使命,遵循“共赢合作”的发展原则,以品牌为导向,渠道为依托,专注于推动中国参茸业发展到国际水平,提升并弘扬中华优秀参茸文化。公司与国内外多家企业同属大韩正韩药业(香港)国际集团属下企业,各企业综合功能齐备,具体分布为:国内企业长白朝鲜自治县正韩参茸有限公司负责原材料GAP种植基地的培植,广东正韩药业股份有限公司为产品深加工和销售。

广东正韩药业股份有限公司在拥有完备的技术基础同时,还吸收了一批有丰富经验的药品、保健品、食品的营销与市场策划高素质人才。公司对参茸行业有着深刻的了解,始终以品牌为发展方向,坚持走“品牌质量效益”的道路。公司制定了明确的品牌推广路线,制定了清晰的品牌发展方向,同时推动了企业利用品牌战略提升销售市场创新能力,增加企业竟争力,力求公司的持续发展和在市场竞争中的领导地位。公司产品投放市场几年来,所有产品以内在质量高、外在包装精美、品种丰富、销售渠道多样化的优势及强大的客户网络支持以及销售培训和有力的推广策略、灵活的合作方式等。目前,正韩企业已在国内各大中城市建立了销售网络,其中被誉为“绿色白金”的拳头产品——正韩牌高丽参(六年根)已远销东南亚和欧、美各国。


英文翻译:Guangdong Zhenghan Pharmaceutical Co., Ltd., a subsidiary of Zhenghan group, takes Changbai Korean Autonomous County as the production raw material planting and collection base, Maoming as the deep processing group, and Dahang Zhenghan (Hong Kong) International Group Company as the comprehensive development group of marketing window. The company introduces excellent production equipment, sets up flow production line workshop, and effectively combines the unique ancient processing technology with modern pharmaceutical production technology for production. After nearly 20 years of steady development, the production and operation of "Zhenghan brand, yigongzhuang brand, zhengshanzhuang brand" and other brands of ginseng antler precious fine products has become a brand, occupying the leading position in the industry and exported to all countries in the world. Since its establishment, the company has taken "dedication to health, creation of harmony" as its mission, followed the development principle of "win-win cooperation", guided by brand and supported by channels, and focused on promoting the development of China's ginseng industry to the international level, and promoting and promoting China's excellent ginseng culture. The company and many enterprises at home and abroad belong to dahangzhenghan Pharmaceutical (Hong Kong) International Group. The comprehensive functions of each enterprise are complete. The specific distribution is: the domestic enterprise Zhenghan ginseng antler Co., Ltd. of Changbai Korean Autonomous County is responsible for the cultivation of raw material gap planting base, and Guangdong Zhenghan pharmaceutical Co., Ltd. is responsible for the deep processing and sales of products. Guangdong Zhenghan Pharmaceutical Co., Ltd. not only has a complete technical foundation, but also absorbs a group of experienced high-quality talents in marketing and marketing of drugs, health products and food. The company has a deep understanding of ginseng antler industry, always takes the brand as the development direction, and adheres to the road of "brand quality and efficiency". The company has formulated a clear brand promotion route and a clear brand development direction. At the same time, it has promoted the enterprise to use the brand strategy to improve the innovation ability of the sales market, increase the competitiveness of the enterprise, and strive for the sustainable development of the company and its leading position in the market competition. In the past few years since the company's products were put on the market, all products have the advantages of high quality, exquisite external packaging, rich varieties, diversified sales channels, strong customer network support, sales training, strong promotion strategies, flexible cooperation methods, etc. At present, Zhenghan enterprises have established a sales network in various large and medium-sized cities in China, among which the key product known as "green platinum" - Zhenghan brand Korean ginseng (six-year root) has been exported to Southeast Asia, Europe and the United States.

本文链接: https://www.waitui.com/brand/219438483.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

药明生物:主要股东拟以每股38.52港元配售1.5亿股

36氪获悉,药明生物公告,1月15日,公司董事会获本公司其中一名主要股东Biologics Holdings知会,其已与摩根士丹利(配售代理)订立大宗交易协议,配售代理已同意以每股38.52港元的价格向独立于本公司且与本公司概无关连的各方配售由Biologics Holdings持有的本公司150,000,000股现有股份。

2小时前

2026年销量目标现分化:传统车企稳健推进,新势力冲刺高增长

2026年车市大幕初启,主流车企陆续披露年度销量目标,勾勒出存量竞争下的发展图景。截至目前,已有吉利、长安、奇瑞、零跑、小米等10余家主流车企明确今年销量目标,总量合计超2155万辆,约相当于2025年国内汽车总销量的63%。整体呈现显著分化:传统自主车企锁定10%至30%的稳健增速,聚焦新能源车与出海双引擎;新势力及跨界品牌则以34%至67.5%的激进目标抢占份额,凸显规模突围诉求。这些数字背后既是车企对市场趋势的判断,更是对产品、技术与渠道体系的综合校验。(中证网)

2小时前

中信建投:集采政策优化,医疗器械细分板块陆续迎来业绩拐点

36氪获悉,中信建投指出,器械集采政策优化、设备招标数据持续改善、渠道库存逐步下降等趋势下,医疗器械细分板块陆续迎来业绩拐点。其中高值耗材板块在集采政策持续优化的背景下,板块估值和业绩确定性有望迎来修复。同时,看好国产医疗器械出海,国际业务长期空间大的公司也有望迎来估值重塑。还看好医疗器械板块的科技创新投资机会,AI医疗、脑机接口、手术机器人、外骨骼机器人等也有望成为投资人重点关注的新科技方向。

2小时前

快手:发行6亿美元于2031年到期的4.125%优先票据

36氪获悉,快手公告,发行6亿美元于2031年到期的4.125%优先票据、9亿美元于2036年到期的4.750%优先票据及人民币35亿元于2031年到期的2.450%优先票据。

2小时前

华尔街大行去年总计减员10600人,为近十年来最高水平

美国最大几家银行去年减员人数创下近十年来新高,高管们试图通过缩减这一通常最高昂的开支项目来控制成本。截至12月底,摩根大通、美国银行、花旗集团、富国银行、高盛集团、摩根士丹利这六大银行员工人数总计109万,较去年同期减少了约10,600人,创2021年以来最低水平。该群体上一次出现如此大规模的减员是在2016年,当时员工人数较前一年减少了约22,000人。(界面)

2小时前

本页详细列出关于正韩的品牌信息,含品牌所属公司介绍,正韩所处行业的品牌地位及优势。
咨询